Free Trial Information
BioCentury | Dec 19, 2011
Company News

Cortical inflammation news

...inhibitors are in preclinical development to treat inflammation and other diseases. Details were not disclosed. Cortical Pty. Ltd....
Read More
BioCentury | Jul 28, 2011
Distillery Therapeutics

Indication: Infectious disease

...Therapeutics LLC's 4-IPP, a small molecule MIF inhibitor, is in preclinical testing to treat cancer. Cortical Pty. Ltd....
Read More
BioCentury | May 19, 2011
Distillery Therapeutics

Indication: Infectious disease

...molecule MIF inhibitor from Advanced Cancer Therapeutics LLC, is in preclinical testing to treat cancer. Cortical Pty. Ltd....
Read More
BioCentury | May 19, 2011
Targets & Mechanisms

Thyroxine: MIFfed about sepsis

...side-effect and dosing profiles," he said. Eric Morand, cofounder and CSO of MIF inhibitor company Cortical Pty. Ltd....
...Park, Ill. Advanced Cancer Therapeutics LLC , Louisville, Ky. Albany Medical College , Albany, N.Y. Cortical Pty. Ltd....
Read More
BioCentury | Aug 29, 2005
Clinical News

Cortical Pty Ltd. preclinical data

In mice with atherosclerotic lesions, oral COR100140 reduced lesion size by 50% vs. vehicle control (p=0.05). The small molecule macrophage migration inhibitory factor (MIF) antagonist also attenuated lesion macrophage numbers by 50% (p=0.05). Data were...
Read More
BioCentury | Aug 29, 2005
Clinical News

Cortical Pty Ltd. preclinical data

In a mouse model of RA, 15 mg/kg COR100140 injections reduced joint swelling (p<0.05) and histological evidence of synovitis, exudates, cartilage degradation and bone damage vs. Enbrel etanercept (all p=0.05). The injections also reduced delayed-type...
Read More
Items per page:
1 - 6 of 6
BioCentury | Dec 19, 2011
Company News

Cortical inflammation news

...inhibitors are in preclinical development to treat inflammation and other diseases. Details were not disclosed. Cortical Pty. Ltd....
Read More
BioCentury | Jul 28, 2011
Distillery Therapeutics

Indication: Infectious disease

...Therapeutics LLC's 4-IPP, a small molecule MIF inhibitor, is in preclinical testing to treat cancer. Cortical Pty. Ltd....
Read More
BioCentury | May 19, 2011
Distillery Therapeutics

Indication: Infectious disease

...molecule MIF inhibitor from Advanced Cancer Therapeutics LLC, is in preclinical testing to treat cancer. Cortical Pty. Ltd....
Read More
BioCentury | May 19, 2011
Targets & Mechanisms

Thyroxine: MIFfed about sepsis

...side-effect and dosing profiles," he said. Eric Morand, cofounder and CSO of MIF inhibitor company Cortical Pty. Ltd....
...Park, Ill. Advanced Cancer Therapeutics LLC , Louisville, Ky. Albany Medical College , Albany, N.Y. Cortical Pty. Ltd....
Read More
BioCentury | Aug 29, 2005
Clinical News

Cortical Pty Ltd. preclinical data

In mice with atherosclerotic lesions, oral COR100140 reduced lesion size by 50% vs. vehicle control (p=0.05). The small molecule macrophage migration inhibitory factor (MIF) antagonist also attenuated lesion macrophage numbers by 50% (p=0.05). Data were...
Read More
BioCentury | Aug 29, 2005
Clinical News

Cortical Pty Ltd. preclinical data

In a mouse model of RA, 15 mg/kg COR100140 injections reduced joint swelling (p<0.05) and histological evidence of synovitis, exudates, cartilage degradation and bone damage vs. Enbrel etanercept (all p=0.05). The injections also reduced delayed-type...
Read More
Items per page:
1 - 6 of 6